Amendments to the Claims

1. (Original) A compound of formula (I)



(I)

wherein

R is H;

Ar is an aromatic group selected from unsubstituted phenyl or phenyl substituted with 1, 2, 3, 4 or 5 substitutents selected from C_1-C_4 alkyl, O(C_1-C_4 alkyl), S(C_1-C_4 alkyl), halo, and phenyl optionally substituted with halo, C_1-C_4 alkyl or O(C_1-C_4 alkyl);

X is unsubstituted phenyl or phenyl substituted with 1, 2, 3, 4 or 5 substituents selected from C_1-C_4 alkyl, O(C_1-C_4 alkyl), and halo;

R' is H or C_1-C_4 alkyl;

each R^1 is independently H or C_1-C_4 alkyl;

wherein each above-mentioned C_1-C_4 alkyl group is optionally substituted with one or more halo atoms;

or a pharmaceutically acceptable salt thereof.

2. (Original) A compound as claimed in claim 1, represented by formula II:



(II)

in which R_2 and R_3 are each independently selected from H, C_1-C_4 alkyl, O(C_1-C_4 alkyl), S(C_1-C_4 alkyl), halo, and phenyl; and

R_4 is selected from H, C_1-C_4 alkyl, O(C_1-C_4 alkyl) and halo;

wherein each above-mentioned C_1-C_4 alkyl group is optionally substituted with one or more halo atoms;
or a pharmaceutically acceptable salt thereof.

3. (Original) A compound as claimed in claim 2, wherein R_2 is selected from C_1-C_2 alkyl, O(C_1-C_2 alkyl), S(C_1-C_2 alkyl), Cl and F wherein each above-mentioned C_1-C_2 alkyl group is optionally substituted with one or more halo atoms.

4. (Original) A compound as claimed in claim 2 or claim 3, wherein R_3 is selected from H, Me and Cl.

5. (Currently amended) A compound as claimed in ~~any one of the claims 2 to~~ claim 4, wherein R_4 is selected from H, C_1-C_2 alkyl, O(C_1-C_2 alkyl), Cl and F wherein each above-mentioned C_1-C_2 alkyl group is optionally substituted with one or more halo atoms.

6-9. (Cancelled)

10. (Currently amended) A method for selectively inhibiting the reuptake of serotonin and norepinephrine in mammals, comprising administering to a patient in need thereof an effective amount of a compound as claimed in ~~any one of claims 1-5~~ claim 1 or 2.

11. (Currently amended) A method for treating a disorder associated with serotonin and norepinephrine dysfunction in mammals, comprising administering to a patient in need thereof an effective amount of a compound as claimed in ~~any one of claims 1-5~~ claim 1 or 2.

12. (Currently amended) A method [[or use]] as claimed in ~~any one of claims 8, 9 and~~ claim 11, wherein the disorder is selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation and pain.

13. (Currently amended) A method [[or use]] as claimed in ~~any one of claims 8, 9 and~~ claim 11, wherein the disorder is selected from depression, stress urinary incontinence and pain.

14. (Currently amended) A method [[or use]] as claimed in ~~any one of claims 8, 9 and~~ claim 11, wherein the disorder is pain.

15. (Currently amended) A composition comprising a compound as claimed in ~~any one of~~

~~claims 1-5~~ claim 1 or 2 together with a pharmaceutically acceptable diluent, excipient or carrier.